(1 - 10 von 11
)
Aphaia Pharma Announces Dosing of First Patient in its ...Fox 59
fox59.com
AP — ... approach to help treat multiple metabolic diseases,” said Kai Deusch, M.D. Ph.D., Chief Business & Medical Officer of Aphaia Pharma.
Aphaia Pharma begins phase 2 trialGreater Zurich Area
www.greaterzuricharea.com
AP — ... continue to evaluate APH-012 in additional indications beyond obesity in the clinic,” said Kai Deusch, Chief Business & Medical Officer.
Aphaia Pharma tritt in Phase II-Studie einpunkt4
punkt4.info
AP — Kai Deusch, Chief Business & Medical Officer, zitiert. „Wir glauben an das Potenzial unseres einzigartigen Ansatzes zur Behandlung verschiedener ...
Swiss Life Sciences DatabaseBiotechgate
www.biotechgate.com
Kai Deusch, M.D., Ph.D., Chief Medical and Business Officer of Aphaia Pharma, added, “This trial builds on the success of our previous Phase 1 study, ...
sortiert nach Relevanz / Datum